InspireMD, Inc. Stock

Equities

NSPR

US45779A8466

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 02:37:05 2024-05-21 pm EDT 5-day change 1st Jan Change
2.33 USD +2.19% Intraday chart for InspireMD, Inc. -2.18% -17.08%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 7.09M Sales 2025 * 14.65M Capitalization 53.41M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 7.53 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.65 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 66
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.64%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : InspireMD, Inc., Q1 2024 Earnings Call, May 14, 2024
Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M MT
Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M MT
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InspireMD Gets CE Mark Recertification From the European Union MT
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America CI
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions CI
Transcript : InspireMD, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Earnings Flash (NSPR) INSPIREMD Reports Q3 Revenue $1.6M MT
InspireMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption Clinical Trial CI
InspireMD, Inc. Supports CMS? Final National Coverage Determination Expanding Coverage of Carotid Stenting to Include Both Asymptomatic and Standard Risk Patients CI
InspireMD, Inc. Announces Management Changes CI
InspireMD Promotes Shane Gleason to Chief Commercial Officer MT
More news
1 day+2.19%
1 week-2.18%
Current month+20.10%
1 month+21.99%
3 months-10.54%
6 months-8.63%
Current year-17.08%
More quotes
1 week
2.18
Extreme 2.18
2.41
1 month
1.81
Extreme 1.81
2.45
Current year
1.81
Extreme 1.81
3.24
1 year
1.58
Extreme 1.58
3.85
3 years
0.81
Extreme 0.8064
6.82
5 years
0.81
Extreme 0.8064
79.50
10 years
0.81
Extreme 0.8064
1 000 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 19-12-31
Director of Finance/CFO 62 11-03-30
Chief Tech/Sci/R&D Officer - 13-12-31
Members of the board TitleAgeSince
Director/Board Member 75 20-10-12
Chief Executive Officer 60 19-12-31
Director/Board Member 77 16-09-05
More insiders
Date Price Change Volume
24-05-21 2.33 +2.19% 8 559
24-05-20 2.28 -0.87% 8,307
24-05-17 2.3 0.00% 14,263
24-05-16 2.3 0.00% 21,160
24-05-15 2.3 -3.44% 28,991

Delayed Quote Nasdaq, May 21, 2024 at 02:37 pm EDT

More quotes
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.28 USD
Average target price
4.5 USD
Spread / Average Target
+97.37%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW